Lung Cancer

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.

Lifileucel was deemed safe and active in patients with previously treated, advanced nonsquamous NSCLC without certain actionable genetic mutations.

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Panelists discuss how treatment selection for early-stage disease depends on lymph node metastasis risk, with SBRT considered for very low-risk peripheral tumors and surgery preferred when staging information is needed.

Panelists discuss how most patients with early-stage disease who would benefit from systemic therapy should receive neoadjuvant treatment, with direct surgery reserved mainly for those with medical contraindications to immunotherapy.

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.